- Design
- Systematic review and meta-analysis of 4 randomised trials
- Population
- 482 long-term care residents with moderate to severe dementia and mild to moderate pain
- Primary outcome
- Observed pain on dementia-specific scales
- Effect
- SMD -0.14 (95% CI -0.39 to 0.11); I² 6%; moderate certainty
A systematic review and meta-analysis in JAMDA (7 October) pooled four randomised trials in the US and Europe, with 482 long-term care residents who had moderate to severe dementia and mild to moderate pain. Residents received paracetamol (acetaminophen) three or four times daily, 2.5 to 3 g a day, for 4 to 13 weeks, compared with placebo in three trials and usual care in one. Pain was measured with dementia-specific observational scales.
Scheduled paracetamol did not reduce pain compared with control (standardised mean difference -0.14, 95% CI -0.39 to 0.11), with little heterogeneity and moderate-certainty evidence. The one trial measuring quality of life found no difference. Adverse events were poorly reported.
Regular paracetamol is often prescribed indefinitely in care homes as a first step, partly because it is seen as harmless. This analysis suggests that, in residents with advanced dementia and mild to moderate pain, it may add pill burden without measurable benefit. Guidelines that recommend paracetamol first line have not changed, and the trials were short and small. The reasonable response is to review standing prescriptions with an observational pain assessment, and stop those without evident benefit, rather than to withhold analgesia from residents in pain.
- Review standing regular paracetamol prescriptions in care-home residents with advanced dementia.
- Assess pain with an observational scale before and after any change in analgesia.
- Consider stopping scheduled paracetamol where there is no evident benefit, and monitor for any return of distress.
- Treat identified painful conditions specifically, such as constipation, pressure areas or osteoarthritis flares.
- Do not withhold analgesia from residents with clear signs of pain.
Why it matters
It challenges a near-universal default that adds pill burden and may mask the need to look for the cause of distress.
Don't overread it
Four short trials with 482 residents cannot exclude a small benefit, and current guidelines still list paracetamol first line.
The statistics, in plain English
A standardised mean difference of -0.14 is a very small effect, and the interval (-0.39 to 0.11) includes no effect. I² of 6% means the four trials agreed. Moderate certainty means the true effect is probably close to this estimate.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for geriatrics, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free